脂必泰胶囊治疗非酒精性脂肪肝临床研究  

Clinical Observation of Zhibitai Capsule on Nonalcoholic Fatty Liver Disease

作　　者：潘哲[1] 张文富[1] 吕建林[1] 韦 於丽丽[1] 黄丽萍 谢冬芳 张晓琳 PAN Zhe;ZHANG Wenfu;LYU Jianlin;WEI Gong;YU Lili;HUANG Liping;XIE Dongfang;ZHANG Xiaolin(Ren’ai Branch of The First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530200,Guangxi,China;School of Science New Medicines of Guangxi University of Chinese Medicine,Nanning 530200,Guangxi,China)

机构地区：[1]广西中医药大学第一附属医院仁爱分院,广西南宁530001 [2]广西中医药大学赛恩斯新医药学院,广西南宁530200

出　　处：《中华中医药学刊》2020年第11期78-80,共3页Chinese Archives of Traditional Chinese Medicine

基　　金：国家自然科学基金(81860839);广西学位与研究生教育改革专项(JGY2015090);广西研究生教育创新计划(YCBZ2019035);广西中医药局自筹科研项目(GZZC2019071)。

摘　　要：目的观察脂必泰对非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)患者肠道菌群、肝功能、血脂的影响。方法 76例NAFLD患者随机分为对照组和治疗组各38例,对照组口服多烯磷脂酰胆碱胶囊,治疗组加服脂必泰胶囊,4个月为1个疗程。比较两组的肠道菌群数量、肠黏膜屏障功能[二胺氧化酶(DAO)、血清内毒素(ET)、降钙素原(PCT)];检测TNF-α、IL-6、ALT、总胆固醇(TC)和甘油三酯(TG),计算胰岛素抵抗指数(HOMA-IR),记录不良反应。结果与治疗前相比,治疗后两组肠杆菌、肠球菌、葡萄球菌数量,ET、DAO、PCT含量,TNF-α、IL-6、HOMA-IR、ALT、AST、TC、TG均明显降低(P<0.05),乳酸菌、双歧杆菌、拟杆菌数量明显增加(P<0.05);治疗组各指标改善均优于对照组(P<0.05)。两组均无明显不良反应出现。结论脂必泰胶囊治疗NAFLD安全有效,值得临床推广。Objective To observe the impacts of Zhibitai Capsule on intestinal flora, liver function, blood lipid and insulin resistance of patients with nonalcoholic fatty liver disease(NAFLD).Methods Seventy-eight cases were randomly divided into control group(38 cases) and study group(38 cases). The control group received Polyene Phosphatidylcholine Capsules and the study group took Zhibitai Capsule additionally. All patients were treated for 4 months. Intestinal flora and intestinalmucosal barrier function(DAO, ET and PCT) were compared. The levels of TNF-α, IL-6, ALT, TC and TGwere determined. HOMA-IR was calculated, and the adverse reactions were recorded. Results After treatment, compared with those before treatment, the numbers of enterobacteriaceae, enterococci and staphylococcus, the levels of ET, DAO, PCT, TNF-α, IL-6, HOMA-IR, ALT, AST, TC and TG decreased greatly. The numbers of lactobacillus, bifidobacteria and bacteroidetes increased greatly(P<0.05). Compared with those in the control group, the indexes mentioned-above improve greatly(P<0.05). No obvious adverse reactions were observed. Conclusion Zhibitai Capsuleissafe and effective for patients with NAFLD, and is worthy of widely clinical use.

关 键 词：非酒精性脂肪性肝病 脂必泰胶囊 疗效 

分 类 号：R259.755[医药卫生—中西医结合]